HOME | CONTACT US
 
Home > CME Portal > Archive    
Pharmacists Roadmap to Pain Management

Zero Tolerance for HAIs:
Pharmacists Take the Next Step

Outcomes Now Available

Herpes Zoster Vaccination: Clinical Update

  

Addressing Opioid Induced Constipation (OIC)

Pain Management Point of Care

OPAT Point of Care

Antifungal Stewardship
Point of Care


  
 
  
Facebook
wbenc  


From Pre-Emptive to Salvage Antifungal Therapy:
Achieving Successful Outcomes

Release Date: April 20, 2009
Credit Expiration Date: April 21, 2010

Credit Hours
Physician CME: 1.0
Pharmacist CPE: 1.0 (0.10 CEUs)

Activity Type
Knowledge-based and competence-based

This is the second activity in a 2-part series.

Educational Overview
When it comes to the management of invasive fungal infections (IFIs), a great deal of progress has been made with significant advancements in prevention, diagnosis, and treatment. Promising new clinical data allow for more targeted antifungal prophylaxis, identifying at-risk patients who would benefit most from this strategy. Evolving radiographic and serologic diagnostic techniques enable clinicians to initiate therapy at the time when therapeutic intervention is most effective. More options when determining treatment lead to better health outcomes for more patients at risk of or who have IFIs.

Today’s healthcare teams are more vigilant in anticipating the possibility of a fungal infection. As a result, survival rates continue to increase while health outcomes improve. These positive efforts must continue. Clinicians, who acquire a level of knowledge and familiarity with new prevention approaches, diagnostic techniques, and management strategies for IFIs, will be empowered to make timely, accurate, evidence-based decisions that benefit their patients.

Target Audience
This activity has been developed for clinical pharmacists, infectious diseases physicians, hematologists/oncologists, and transplant physicians responsible for the management of IFIs.

Purpose Statement
The purpose of this activity is to educate physicians and pharmacists involved in the management of patients at risk of invasive fungal infections (IFIs) on treatment of IFIs. With this knowledge, healthcare professionals will be able to select appropriate antifungal therapy at various stages of infection—from pre-emptive to salvage therapy.

Learning Objectives
At the conclusion of this activity, participant should be able to

  • Distinguish between the advantages of a pre-emptive strategy and empiric treatment when managing patients with IFIs
  • Identify the causes of treatment failure and recognize options for salvage therapy

Faculty
Elizabeth S. Dodds Ashley, PharmD, MHS, BCPS
Infectious Diseases Clinical Pharmacist
University of Rochester Medical Center
Rochester, NY

John R. Perfect, MD
Professor of Medicine
Associate Professor of Medicine (Infectious Diseases)
Duke University Medical Center
Durham, NC

Accreditation
Physicians
Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Center for Independent Healthcare Education (Center) and Vemco MedEd. Center is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: Center designates for this activity a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity was originally released as a Live Webcast. Only those who did not claim credit for the live activity can claim credit for this activity.

Pharmacists
Accreditation Council for Pharmacy EducationAccreditation Statement: Center for Independent Healthcare Education (Center) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credit Designation: Center has assigned 1.0 contact hour (0.1 CEUs) of continuing pharmacy education credit for participation in this activity. ACPE Universal Activity Number: 473-999-09-007-H01-P

This activity was originally released as a Live Webcast with ACPE Universal Activity Number: 473-999-09-001-L01-P. Only those who did not claim the credit for the live activity can claim credit for this activity

Estimated time to complete activity: 1.0 hour

Method of Participation and Instruction for Credit

  1. Review the entire CME/CE information including target audience, learning objectives, and disclosures.
  2. Review the On-Demand Webinar in its entirety.
  3. Print and complete the Post Test, Evaluation, and Credit Application form.
  4. Mail the completed Post Test, Evaluation, and Credit Application form to Vemco MedEd, 245 US Highway 22, Suite 304, Bridgewater, NJ 08807 Or Fax to (908) 235-4222.
Documentation of credit will be mailed within 4 weeks of receipt of the completed Post Test, Evaluation, and Credit Application form.

Disclosures
Center for Independent Healthcare Education requires faculty, planners, and others who are in a position to control the content of continuing education activities to disclose to the audience any real or apparent conflict of interest related to the activity. All identified conflicts of interest are reviewed to ensure fair balance, objectivity, and scientific rigor in all activities. The faculty is further required to disclose discussion of off-label uses in their presentations.

Faculty
Elizabeth S. Dodds Ashley, PharmD
Grant/Research Support: Astellas and Schering-Plough
Advisory Boards: Astellas
Promotional Speakers Bureau: Schering-Plough and Merck

John R. Perfect, MD
Grant/Research Support: Enzon, Pfizer, Schering-Plough, Merck, and Astellas
Research Support: Schering-Plough, NeuTec, and Cubist
Advisor/Consultant: Enzon, Pfizer, Schering-Plough, Astellas, and Merck

Planning Committee Members
Employees of Center for Independent Healthcare Education and Vemco MedEd have no relevant financial relationships to disclose.

Off-label Use Disclosure
In this activity, off-label use of the following antifungal agents is discussed: voriconazole (for empiric therapy in febrile neutropenic patients and for refractory infections caused by Aspergillus, Candida, and Cryptococcus); caspofungin (for refractory infections caused by Candida); posaconazole (for refractory infections caused by Aspergillus, Fusarium, and Cryptococcus); voriconazole/caspofungin combination therapy (for treatment of invasive aspergillosis).

Joint Sponsorship
This activity is jointly sponsored by Center for Independent Healthcare Education and Vemco MedEd.

Commercial Support
This activity is supported by an educational grant from Schering-Plough Corporation.

Fee
There is no fee associated with this activity.

Hardware/Software Requirements
Web Browser
Internet Explorer or Mozilla
Note: Please disable any “pop-up blocker” features.

Software
Flash Player to view the presentations
Adobe Acrobat Reader version 4 or above to view PDF files (If you do not have Acrobat Reader, you can download it for free from http://get.adobe.com/reader)

Connection Speed
Cable, DSL, or better of at least 300 kbps

Hardware
PC or Apple to view the presentations
Audio Speakers

System Check
Please e-mail any questions or concerns to info@vemcomeded.com.

Copyright Statement
Copyright © 2009 Vemco MedEd, LLC. All Rights Reserved. Permission for accreditation use granted to Center for Independent Healthcare Education.

Disclaimer
The opinions expressed in this educational activity are those of the faculty and do not reflect the views of Center for Independent Healthcare Education (Center) and Vemco MedEd. This educational activity may discuss off-label and/or investigational uses and dosages for therapeutic products/procedures that have not been approved by the United States Food and Drug Administration (FDA). Center and Vemco MedEd do not recommend the use of any product/procedure outside of the labeled indications. A qualified healthcare professional should be consulted before using any therapeutic product/procedure discussed. Clinicians should verify all information and data before treating patients or employing any therapies described in this continuing education activity. Please refer to the prescribing information for each product/procedure for approved indication, contraindications, and warnings.

Privacy Policy
http://www.vemcomeded.com/privacy.asp

Contact Information
For questions regarding the accreditation of this activity, please contact Center for Independent Healthcare Education at info@jointsponsor.com

Start Activity

  

By clicking on the icon to begin the educational activity, I acknowledge that I have read the entire CME/CPE information.

  

Home | About Us | What We Do | CME Portal | Register for Programs | Outcomes Reports | Contact Us | Legal | Privacy Statement
© 2019 Vemco MedEd, LLC I All Rights Reserved.